Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis

Blood

Volumn 95, Issue 2, 2000, Pages 543-550

  Colman, Robert W ^a,b,c   Jameson, Bradford A ^b   Lin, Yingzhang ^c   Johnson, Donald ^a   Mousa, Shaker A ^c  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KININOGEN;

ANGIOGENESIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN;

ALLANTOIS; AMINO ACID SEQUENCE; ANIMALS; CARRIER PROTEINS; CELL DIVISION; CELLS, CULTURED; CHEMOTAXIS; CHICK EMBRYO; CHORION; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; MICROFILAMENT PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDE FRAGMENTS; PEPTIDES; PROTEIN CONFORMATION; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE DELETION; SEQUENCE HOMOLOGY, AMINO ACID; SURFACE PROPERTIES; UMBILICAL VEINS;

EID: 0034651013     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.2.543     Document Type: Article

References (51)

1. Neilsen LS, Kellerman GM, Behrendt N, Picone R, Dano K, Blasi F. A 55.000-60,000 Mr receptor protein for urokinase-type plasminogen activator. J Biol Chem. 1988:263:2358-2363.
2. Estreicher A, Muhlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol. 1990:111:783-792.
3. Multhaupt HA, Mazar A, Cines DB, Warhol MJ, McCrae KR. Expression of urokinase receptors by human trophoblast. Ahistochemical and ultrastructural analysis. Lab Invest. 1994;71:392-400.
4. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem. 1994:269:32,380-32,388.
5. Behrendt N, Ploug M, Pattny L, Houen G, Blasi F, Dano K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem. 1991:266:7842-7847.
6. Kitamura N, Kitagawa H, Fukushima D, Takagaki Y, Miyata T, Nakanishi S. Structural organization of the human kininogen gens and a model for its evolution. J Biol Chem. 1985;260:8610-8617.
7. Puri RN, Zhou F, Hu CJ, Colman RF, Colman RW. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood. 1991;77:500-507.
8. Kunapuli SP, Bradford HN, JamesonBA, etal. f Thrombin-induced platelet aggregation is inhibited by the heptapeptide Leu271-Ala277 domain 3 in the heavy chain of high molecular weight kininogen. J Biol Chem. 1996:271:11,228-11,234.
9. Herwald H, Hasan AAK, Godovac-Zimmermann J, Schmaier AH, Muller-Estert W. Identification of an endothelial cell binding site on kininogen domain D3. J Biol Chem. 1995:270:14,634-14,642. 10. Scott CF, Silver LD, Schapira M, Colman RW. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity: evidence that this molecule exists as a procofactor. J Clin Invest. 1984;73:954-962.
10. DeLa Cadena R A, Colman RW. The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc-dependent binding to an anionic surface. Protein Sei. 1992:1:151-160.
11. Kunapuli SP, DeLa Cadena RA, Colman RW. Deletion mutagenesis of high molecular weight kininogen light chain: identification of two anionic surface binding subdomains. J Biol Chem. 1993; 268:2486-2492.
12. Wachtfogel YT, DeLa Cadena RA, Kunapuli SP, et al. High molecular weight kininogen binds to Mac-1 on neutrophils by its heavy chain (domain 3) and its light chain (domain 5). J Biol Chem. 1994:269:19,307-19,312.
13. Khan MMH, Kunapuli SP, Un YZ, et al. Three noncontiguous peptides comprise binding sites on high molecular weight kininogen to neutrophils. Am J Physiol. 1998;275:H145-H150.
14. Hasan AAK, Cines DB, Herwald H, Schmaier AH, Muller-Esterl W. Mapping the cell binding site on high molecular weight kininogen domain 5. J Biol Chem. 1995:270:19,256-19,261.
15. Gustafson EJ, Lukasiewicz H, Wachtfogel YT, et al. High molecular weight kininogen inhibits fibrinogen binding to cytoadhesions of neutrophils and platelets. J Cell Biol. 1939:109:377-387.
16. Asakura S, Hurley RW, Skorstengaard K, Ohkubo I, Mosher DF. Inhibition of cell adhesion by high molecular weight kininogen. J Cell Biol. 1992:116: 465-476.
17. Tait JF, Fujikawa K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J Biol Chem. 1987;262:11,651 -11,656.
18. Colman RW, Pixley RA, Najamunnisa S, et al. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2+3 of the urokinase receptor. J Clin Invest. 1997:100:1481-1487.
19. Un Y, Harris RB, Yan WY, McCrae KR, Colman RW. Inhibition of prourokinase-activated fibrinolysis on endothelial cell surfaces by high molecular weight kininogen peptides. Blood. 1997:90:690697.
20. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc Res. 1977;14:53-65.
21. Gross JL, Moscatelli D, Rifkin DB. Increased capillary endothelial cell protease activity in response to angiogenic stimuli in vitro. Proc Natl Acad Sei USA. 1983:80:2623-2627.
22. Lin Y, Harris RB, Van W, McCrae KR, Zhang H, Colman RW. High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinasedependent plasmin formation. Blood. 1997;90: 690-697.
23. Bozarth JM, Penno MB, Mousa SA. An improved method for the quantitation of cellular migration: role of avβ3 integrin in endothelial and smooth muscle cell migration. Methods in Cell Science. 1997;19:179-187.
24. Kültz D, Samera M, Brug M. Hyperosmolarity causes growth arrest of murine kidney cells. J Biol Chem. 1998:273:13,645-13,651.
25. Jameson BA. Modelling in peptide design [news]. Nature. 1989:341:465-466.
26. Jameson BA, McDonnell JM, Marini JC, Korngold R. A rationally designed CD4 analogue inhibits experimental allergic encephalomyelitis [comments]. Nature. 1994:368:744-746.
27. Habazettl J, Gondol D, Wiltscheck R, Otlewski J, Schleicher M, HolakTA. Structure of hisactophilin is similar to interleukin-1 beta and fibroblast growth factor. Nature. 1992:359:855-858.
28. Habazettl J, Schleicher M, Otlewski J, Holak TA. Homonuclear three-dimensional NOE-NOE nuclear magnetic resonance/spectra for structure determination of proteins in solution. J Mol Biol. 1992:228:156-169.
29. Bradford HN, DeLa Cadena RA, Kunapuli SP, Dong JF, Lopez JA, Colman RW. Human kininogens regulate thrombin binding to platelets through the GPIb-IX-V complex. Blood. 1997;90: 1508-1515.
30. O'Reilly M, Holmgren L, Shing Y, et al. A novel angiogenesis inhibitor that mediates the suppression of metastasis by a Lewis lung carcinoma. Cell. 1994;79:315-328.
31. Pollanen J, Stephens RW, Vaheri A. Directed plasminogen activation at the surface ot normal and malignant cells. Adv Cancer Res. 1991 ;57: 273-328.
32. Barnathan ES, Kuo A, Kariko K, et al. Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and mRNA. Blood. 1990:76:1795-1806.
33. Roldan AL, Cubellis MV, Masucci MT, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface-plasmin dependent proteolysis. EMBO J. 1990:9:467-474.
34. Ploug M, Rönne E, Behrendt N, Jensen AL, Blasi F, Dano K. Cellular receptor for urokinase plasminogen activator; carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem. 1991:266:1926-1933.
35. Hall SW, Humphries JE, Gonias SL. Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem. 1991:266:12,329-12,336.
36. Odekon LE, Sato Y, Rifkin DB. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol. 1992; 150:258-263.
37. Bacharach E, Itin A, Keshet E. In vivo patterns of expression of urokinase and its inhibitor PA1-1 suggest a concerted role in regulating physiologi-cal angiogenesis. Proc Natl Acad Sei USA. 1992;89:10,686-10,690.
38. Van Hinsbergh VWM, Koolwijk P, Hanemaaijer R. Role of fibrin and plasminogen activators in repair-associated angiogenesis. In vitro studies with human endothelial cells. In: Goldberg ID, Rosen EM, eds. Regulation of Angiogenesis. Basel, SwitzerJandL.Birkhauser Verlag; 1997:391-399.
39. Pepper MS, Beli D, Montesano R, Ore! L, Vassalli JD. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. J Cell Biol. 1990:111:743-755.
40. Pepper MS, Sappino AP, Stocklin R, Montesano R, Orci L, Vassalli JD. Upregulation of urokinase receptor expression on migrating endothelial cells. J Cell Biol. 1993:122:673-684.
41. Higazi A, Cohen RL, Henkin J, Kniss D, Schwartz BS, Cinés DB. Enhancement of the enzymatic activity of single-chain urokinase plasminogen activator by soluble urokinase receptor. J Biol Chem. 1995:21:17,375-17,380.
42. Higazi A, Bdeir K, Hiss E, et al. Lysis of plasma clots by urokinase-soluble urokinase receptor complexes. Blood. 1998:92:2075-2083.
43. Motta G, Rojkjaer R, Hasan AAK, Cines DB, SchmaierAH. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells-a novel mechanism for contact activation. Blood. 1998:91:516-528.
44. Higazi AA, Mazar A, Wang J, et at. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood. 1996:87:3545-3549.
45. Villanueva GB, Leung L, Bradford H, Colman RW. Conformation of high molecular weight kininogen: effects of kailikrein and factor Xla cleavage. Biochem Biophys Res Commun. 1989:158:72-79.
46. Weisel JW, Nagaswami C, Woodhead JL, DeLa Cadena RA, Page JD, Colman RW. The shape of high molecular weight kininogen: organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J Biol Chem. 1994;269: 10,100-10,106.
47. Hasan AAK, Zisman T, Schmaier AH. Identification of cytokeratin 1 as a binding protein and presentation receptor for kininogens on endothelial cells. Proc Natl Acad Sei U S A. 1998:95:36153620.
48. Ghebrehiwet B, Um BL, Peerschke El, Willis AC, Reid KB. Isolation, cDNA cloning, and overexpression of a 33-kD ceil surface glycoprotein that binds to the globular "heads" of C1q. J Exp Med. 1994;179:1809-1821.
49. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood. 1997;90:3819-3843.
50. Xue W, Kindzelskii AL, Todd RF III, Petty HR. Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol. 1994:152:4630-4640.
51. Sitrin RG, Todd RF III, Albrecht E, Gyetko MR. The urokinase receptor (CD87) facilitates CD11b/ CD18-mediated adhesion of human monocytes. J Clin Invest. 1996:97:1942-1951.